Soleno Therapeutics SLNO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Soleno Therapeutics (SLNO) Core Market Data and Business Metrics
Latest Closing Price
$73.67Price-Earnings Ratio
-16.82Total Outstanding Shares
45.86 Million SharesDividend
No dividendSIC Description
Electromedical & Electrotherapeutic ApparatusPrimary Exchange
NASDAQHeadquarters
100 Marine Parkway, Suite 400, Redwood City, CA, 94065
Historical Stock Splits
If you bought 75 shares of SLNO before October 6, 2017, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| August 26, 2022 | 1-for-15 (Reverse Split) |
| October 6, 2017 | 1-for-5 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 695,099 Shares | 7.18 | 3/14/2025 | 4,987,722 Shares |
| 435,572 Shares | 11.04 | 2/28/2025 | 4,807,491 Shares |
| 402,855 Shares | 11.27 | 2/14/2025 | 4,540,445 Shares |
| 386,515 Shares | 11.25 | 1/31/2025 | 4,348,846 Shares |
| 497,364 Shares | 9.51 | 1/15/2025 | 4,731,294 Shares |
| 646,376 Shares | 7.1 | 12/31/2024 | 4,591,099 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $213.03 Million |
| Net Cash Flow From Investing Activities, Continuing | $-225.68 Million |
| Net Cash Flow, Continuing | $-81.75 Million |
| Net Cash Flow | $-81.75 Million |
| Net Cash Flow From Investing Activities | $-225.68 Million |
| Net Cash Flow From Financing Activities | $213.03 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $-175.85 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-175.85 Million |
| Research and Development | $78.57 Million |
| Other Operating Expenses | $107.12 Million |
| Nonoperating Income/Loss | $11.82 Million |
| Net Income/Loss Attributable To Parent | $-175.85 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-175.49 Million |
| Other Comprehensive Income/Loss | $361,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-175.49 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $30.09 Million |
| Liabilities And Equity | $330.97 Million |
| Intangible Assets | $6.80 Million |
| Current Assets | $293.89 Million |
| Noncurrent Assets | $37.08 Million |
| Accounts Payable | $8.88 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||